Standout Papers

Farnesoid X nuclear receptor ligand obeticholic acid... 2004 2026 2011 2018 1.7k
  1. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial (2014)
    Brent A. Neuschwander‐Tetri, Rohit Loomba et al. The Lancet
  2. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis† ‡ (2004)
    Kittichai Promrat, Glen Lutchman et al. Hepatology
  3. Acute liver failure (2008)
    William M. Lee, Robert H. Squires et al. Hepatology
  4. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease (2018)
    Mohammad Shadab Siddiqui, Raj Vuppalanchi et al. Clinical Gastroenterology and Hepatology

Immediate Impact

3 by Nobel laureates 1 from Science/Nature 143 standout
Sub-graph 1 of 13

Citing Papers

Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis
2024 Standout
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
2023 Standout
96 intermediate papers

Works of Edward Doo being referenced

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
2014 Standout
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis† ‡
2004 Standout
and 6 more

Author Peers

Author Last Decade Papers Cites
Edward Doo 3631 5073 340 1258 41 6.5k
Bilal Hameed 2392 3911 267 1252 66 5.5k
Hari S. Conjeevaram 6765 7584 220 924 82 9.4k
Samuele De Minicis 3132 4166 282 1049 56 7.0k
Naga Chalasani 2077 3191 392 969 68 5.0k
Marcello Persico 3172 4154 509 954 197 6.3k
Jay H. Lefkowitch 4327 4817 328 509 136 8.3k
Frank A. Anania 2575 5535 134 2046 81 8.5k
Patrick Hillon 2613 2885 429 546 135 5.4k
I M Murray-Lyon 6176 5274 652 383 71 8.8k
Coleman I. Smith 6449 7749 76 1470 52 9.6k

All Works

Loading papers...

Rankless by CCL
2026